alexa Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis.
Pharmaceutical Sciences

Pharmaceutical Sciences

Journal of Applied Pharmacy

Author(s): Park T, Choi JY

Abstract Share this page

Abstract PURPOSE: To determine the efficacy and safety of dutasteride, alone or in combination, versus a placebo or control, used for the treatment of benign prostatic hyperplasia. METHODS: Pubmed(®) and the Cochrane Library were searched for randomized controlled trials longer than 6 months in duration. The subjects in the trials were men aged 40 or over, with moderate to severe symptoms of benign prostatic hyperplasia (BPH) as determined by International Prostate Symptom Score (IPSS). We pooled data from a total of nine different clinical trials. RESULTS: Dutasteride was superior to placebo in improving urinary symptoms measured by IPSS (∆ = -1.78, 95 \% CI -3.01 to -0.55), peak urinary flow (Q max) (∆ = 1.27 mL/s, 95 \% CI 0.97-1.57), and change in total prostate volume (TPV) (∆ = -17.40 cm(3), 95 \% CI -25.77 to -9.02) while it resulted in more frequent drug-related adverse events (RR 1.35, 95 \% CI 1.19-1.54). Combination therapy with dutasteride and tamsulosin resulted in significantly greater improvements in IPSS and Q max than tamsulosin monotherapy (∆ = -1.80 mL/s, 95 \% CI -1.81 to -1.79 and ∆ = 1.60 mL/s, 95 \% CI 1.59-1.61, respectively). When comparing dutasteride with finasteride, no significant differences in symptom improvement or the rate of adverse events were observed. CONCLUSIONS: Dutasteride can be used to improve urinary symptoms (IPSS and Q max) and reduce TPV but with awareness of its potential adverse events. Combination therapy with tamsulosin can be considered when further improvements in symptoms are desired. This article was published in World J Urol and referenced in Journal of Applied Pharmacy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 8th Annual Pharmaceutical Analysis Congress
    Sep 25-27, 2017 Vienna, Austria
  • 12th World Pharma Congress
    October 16-18, 2017 Budapest, Hungary

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords